TP53 and KRAS variants identified in cohort 2
| Patient number . | Clinical risk group . | Gene . | AA change . | AF at initial diagnosis, % . |
|---|---|---|---|---|
| 353 | MR | TP53 | F113L | 3.0 |
| 327 | MR | TP53 | R248W | 8.4 |
| 227 | MR | TP53 | R213X | 10.1 |
| 215 | MR | TP53 | T253S | 13.6 |
| 386 | SR | TP53 | Y234C | 84.5 |
| 191 | MR | KRAS | G12D | 11.3 |
| 289 | MR | KRAS | G13D | 12.9 |
| 166 | MR | KRAS | G13C | 27.6 |
| 194 | MR | KRAS | A146V | 34.7 |
| 187 | MR | KRAS | G12V | 40.6 |
| Patient number . | Clinical risk group . | Gene . | AA change . | AF at initial diagnosis, % . |
|---|---|---|---|---|
| 353 | MR | TP53 | F113L | 3.0 |
| 327 | MR | TP53 | R248W | 8.4 |
| 227 | MR | TP53 | R213X | 10.1 |
| 215 | MR | TP53 | T253S | 13.6 |
| 386 | SR | TP53 | Y234C | 84.5 |
| 191 | MR | KRAS | G12D | 11.3 |
| 289 | MR | KRAS | G13D | 12.9 |
| 166 | MR | KRAS | G13C | 27.6 |
| 194 | MR | KRAS | A146V | 34.7 |
| 187 | MR | KRAS | G12V | 40.6 |
Among the 226 analyzed T-ALL patients, 5 non-relapsing patients showed functionally damaging TP53 variants and another 5 functionally damaging variants of KRAS at initial diagnosis. None of the relapsing patients harbored TP53 or KRAS variants.
AA, amino acid; MR, medium risk; SR standard risk.